Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Show other versions (1)

OBJECTIVE: To determine the relation between concentrations of prostate specific antigen at age 60 and subsequent diagnosis of clinically relevant prostate cancer in an unscreened population to evaluate whether screening for prostate cancer and chemoprevention could be stratified by risk. DESIGN: Ca...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Vickers, A, Cronin, A, Björk, T, Manjer, J, Nilsson, P, Dahlin, A, Bjartell, A, Scardino, P, Ulmert, D, Lilja, H
Formato:	Journal article
Idioma:	English
Publicado em:	2010

Registos relacionados

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
Por: Vickers, A, et al.
Publicado em: (2010)

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
Por: Lilja, H, et al.
Publicado em: (2011)

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
Por: Klein, R, et al.
Publicado em: (2012)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
Por: Lilja, H, et al.
Publicado em: (2008)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
Por: Ulmert, D, et al.
Publicado em: (2008)

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
Por: Vickers, A, et al.
Publicado em: (2011)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
Por: Savage, C, et al.
Publicado em: (2010)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
Por: Lilja, H, et al.
Publicado em: (2008)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
Por: Berglund Göran, et al.
Publicado em: (2008-02-01)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
Por: Ulmert, D, et al.
Publicado em: (2008)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
Por: Evans-Axelsson, S, et al.
Publicado em: (2012)

Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
Por: O'Brien, M, et al.
Publicado em: (2011)

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
Por: Vickers, A, et al.
Publicado em: (2007)

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
Por: Lilja, H, et al.
Publicado em: (2007)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
Por: Vickers, A, et al.
Publicado em: (2010)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
Por: Vickers, A, et al.
Publicado em: (2010)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
Por: Christensson, A, et al.
Publicado em: (2011)

Five genetic variants associated with prostate cancer.
Por: Vickers, A, et al.
Publicado em: (2008)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
Por: Vickers, A, et al.
Publicado em: (2009)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
Por: Ulmert, D, et al.
Publicado em: (2009)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
Por: Siivola, P, et al.
Publicado em: (2000)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
Por: Cao, Y, et al.
Publicado em: (2002)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
Por: Steuber, T, et al.
Publicado em: (2007)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
Por: Vickers, A, et al.
Publicado em: (2011)

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.
Por: Ulmert, D, et al.
Publicado em: (2006)

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
Por: Wenske, S, et al.
Publicado em: (2009)

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
Por: Ulmert, D, et al.
Publicado em: (2012)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
Por: Vickers, A, et al.
Publicado em: (2009)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
Por: Michael Tzeng, et al.
Publicado em: (2021-08-01)

Biology of prostate-specific antigen
Por: Lilja, H
Publicado em: (2003)

Biology of prostate-specific antigen.
Por: Lilja, H
Publicado em: (2003)

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
Por: O'Brien, M, et al.
Publicado em: (2009)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
Por: Vickers, A, et al.
Publicado em: (2010)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
Por: Vickers, A, et al.
Publicado em: (2010)

Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Por: Klein, R, et al.
Publicado em: (2010)

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
Por: Olsson, A, et al.
Publicado em: (2005)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
Por: Vickers, A, et al.
Publicado em: (2008)

The continuing role of prostate-specific antigen as a marker for localized prostate cancer: 'do not throw the baby out with the bath water'.
Por: Challacombe, B, et al.
Publicado em: (2009)

Screening for prostate cancer: an update.
Por: Shariat, S, et al.
Publicado em: (2008)

Tumor markers in prostate cancer I: blood-based markers.
Por: Shariat, S, et al.
Publicado em: (2011)